Symmetric Dimethylarginine in Cats with Hypertrophic Cardiomyopathy and Diabetes Mellitus by Langhorn, R. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Symmetric Dimethylarginine in Cats with Hypertrophic Cardiomyopathy and Diabetes
Mellitus
Langhorn, R.; Kieler, I. N.; Koch, J.; Christiansen, L. B.; Jessen, L. R.
Published in:






Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Langhorn, R., Kieler, I. N., Koch, J., Christiansen, L. B., & Jessen, L. R. (2018). Symmetric Dimethylarginine in
Cats with Hypertrophic Cardiomyopathy and Diabetes Mellitus. Journal of Veterinary Internal Medicine, 32(1),
57-63. https://doi.org/10.1111/jvim.14902
Download date: 03. Feb. 2020
Symmetric Dimethylarginine in Cats with Hypertrophic
Cardiomyopathy and Diabetes Mellitus
R. Langhorn , I.N. Kieler, J. Koch, L.B. Christiansen*, and L.R. Jessen*
Background: Symmetric dimethylarginine (SDMA) has been increasingly used as a marker of early chronic kidney disease
(CKD) in cats, but little is known about the inﬂuence of comorbidities on SDMA in this species.
Hypothesis: Hypertrophic cardiomyopathy (HCM) and diabetes mellitus (DM), independently of CKD, are associated
with changes in serum SDMA.
Animals: Ninety-four cats (17 with CKD, 40 with HCM, 17 with DM, and 20 healthy controls).
Methods: Case-control study. Clinical examination, echocardiography, ECG, blood pressure, CBC, biochemistry, thyrox-
ine, and SDMA measurement were performed. Urinalysis was performed in controls and cats with CKD and DM. Analysis
of variance was used to compare overall diﬀerences in the log-transformed SDMA data among groups. A random forest
algorithm was applied to explore which clinical and other factors inﬂuenced serum SDMA.
Results: Median (range) serum SDMA for the renal group (positive control) was 19 (10–93) lg/dL, whereas for the con-
trol group (negative control), it was 10 (5–15) lg/dL. For the cardiac and diabetic groups, serum SDMA was 9 (4–24) lg/dL
and 7 (3–11) lg/dL, respectively. The renal group had signiﬁcantly higher SDMA concentrations and the diabetic group
signiﬁcantly lower SDMA concentrations compared to all other groups.
Conclusions and Clinical Importance: Serum SDMA concentrations in cats with HCM were not signiﬁcantly diﬀerent from
those of healthy control cats. Cats with DM, however, had signiﬁcantly lower SDMA concentrations than controls, a ﬁnding
that needs further investigation and should be kept in mind when evaluating renal function of cats with this endocrinopathy.
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Chronic kidney disease (CKD) is the most commonmetabolic disease in cats.1 Its prevalence increases
with age, reaching >80% in cats older than 15 years.2
Although the diagnosis is often straight forward once
cats reach azotemic stages of disease, earlier diagnosis is
desirable because recent studies suggest a possible bene-
ﬁt of initiating renoprotective nutritional treatment
before this stage.3,4
Symmetric dimethylarginine (SDMA) is a by-product
of normal intracellular protein metabolism, released after
symmetric methylation of arginine residues and subse-
quent protein hydrolysis.5,6 The molecule is almost solely
cleared by glomerular ﬁltration, where it is freely ﬁltered
because of its small molecular size and positive charge.5
In cats with CKD, SDMA has an inverse linear relation-
ship with glomerular ﬁltration rate (GFR)7 and
increases when GFR decreases by approximately 25%,
with a mean time of 17 months before an increase in
serum creatinine concentration.8 Consequently, SDMA
has become a renal marker of considerable interest in
recent years.
Although SDMA reﬂects kidney function, it has not
been thought to aﬀect it or to directly contribute to
progression of renal disease.9 A recent study, however,
suggested that SDMA might not be an inert molecule
with respect to renal pathology.10 Additionally, SDMA
appears to play an important role in vascular homeosta-
sis, and thus the eﬀects of and on SDMA of nonrenal
disease still are being clariﬁed. Older cats with CKD
frequently are aﬄicted with comorbidities, 2 of the most
common being hypertrophic cardiomyopathy (HCM)
and diabetes mellitus (DM). Eliminating an inﬂuence of
such comorbidities on SDMA in cats is important to
conﬁrm its reliability as a renal marker.
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One study of HCM in humans reported increased
serum SDMA concentrations in patients with this
disease.11 The cause has not been determined with cer-
tainty, but the eﬀect may be endothelial dysfunction of
which SDMA is believed to be a mediator.6 The vascu-
lar endothelium releases vasoactive substances such as
nitric oxide (NO) which help maintain vascular integ-
rity and regulate its homeostasis.12,13 Nitric oxide
inﬂuences vascular tone, blood pressure, and regional
blood ﬂow while also having anti-inﬂammatory,
antithrombotic, and antiatherosclerotic eﬀects.6 SDMA
is believed to decrease NO synthesis by competing with
its substrate, arginine, for cellular uptake.14,15 Addi-
tionally, endothelial dysfunction also may be mediated
through proinﬂammatory eﬀects of SDMA on the vas-
cular wall.10,16 Because abnormal coronary vasculature
is believed to be an important factor in the pathophys-
iology of HCM in cats, as in humans,11,17 evaluating
SDMA in cats with HCM is of interest.
In humans with DM, interpretation of SDMA is
complicated because of the frequent development of
diabetic nephropathy.18–20 In cats, however, renal dis-
ease does not appear to occur more commonly in dia-
betic individuals than in age-matched controls.21
Therefore, a possible inﬂuence of DM on SDMA might,
in fact, be more apparent in cats than in humans.
The aim of our study was to establish whether HCM
and DM, independently of CKD, are associated with
changes in serum SDMA in cats.
Materials and Methods
Cats were categorized according to disease as a renal group
(cats with azotemic renal disease deﬁned as serum creatinine con-
centration >140 lmol/L and urine speciﬁc gravity <1.035), a car-
diac group (cats with HCM deﬁned as maximal end-diastolic
thickness of the interventricular septum or left ventricular caudal
free wall >5.5 mm according to a conventional echocardiographic
protocol),22 a diabetic group (cats with DM deﬁned as hyper-
glycemia and glucosuria in the presence of corresponding clinical
signs), and a healthy control group (cats deemed healthy based on
clinical examination, echocardiography, ECG, and clinical pathol-
ogy [CBC, biochemistry, urinalysis, and serum thyroxine results]).
All 4 groups of cats were included retrospectively from previous
prospective studies performed by the authors. The renal group was
included as a positive control and the healthy control group as a
negative control for the 2 groups of cats to be investigated (car-
diac and diabetic groups). Each of the prospective studies had
been approved by the ethical committee of the Department of
Veterinary Clinical Sciences, University of Copenhagen, Denmark,
and informed owner consent for participation had been obtained.
All cats had been included through the internal medicine and
cardiology services at the University Hospital for Companion Ani-
mals, University of Copenhagen, Denmark. For all cats, a clinical
examination had been carried out, and echocardiography, ECG,
CBC, biochemistry, and thyroxine measurement had been per-
formed. Blood pressure measurements had been performed for the
majority of cats. Urinalysis had been performed for all cats in the
renal, diabetic, and control groups.
Cats were excluded from the study if they were <1 year of age.
For each of the 3 disease groups, cats with evidence of comorbidi-
ties were excluded. Cats with HCM were excluded if abnormalities
on CBC, biochemistry, serum thyroxine concentration, or blood
pressure were identiﬁed. Because urinalyses and abdominal
ultrasound examinations were not available for this group of cats,
the risk of inclusion of cats with stage 1 CKD according to guide-
lines of the International Renal Interest Society (IRIS) could not
be eliminated, but all cats with serum creatinine concentration
>140 lmol/L were excluded. Cats with DM were excluded if
abnormalities on CBC, biochemistry (other than those associated
with DM), serum thyroxine concentration, or echocardiography
were identiﬁed. Cats with renal disease were excluded if abnormal-
ities on CBC, biochemistry (other than those associated with
CKD), serum thyroxine concentration, or echocardiography were
identiﬁed.
Serum for measurement of SDMA was obtained from the
departmental biobank. Serum had been collected into 4 mL gel
separator tubes, allowed to clot for 15 minutes at room tempera-
ture, centrifuged at 2,5009g for 5 minutes, separated, and stored
in cryovials at 80°C within 6 hours of blood collection. Samples
had been stored for a maximum of 6 years before thawing and
shipping to IDEXX laboratoriesa for SDMA analysis.
Statistical Analysis
Data were analyzed by commercial statistical software.b Normal-
ity of data was assessed visually by histograms and qq-plots. If data
were not found to be normally distributed, they were log-trans-
formed and reassessed. Analysis of variance (ANOVA) with age as a
cofactor was used to compare overall diﬀerences in the log-trans-
formed SDMA data among the 4 groups; cardiac, diabetic, renal,
and control, respectively. Posthoc analysis of the 2-way ANOVA
then was performed by Tukey Honest Signiﬁcant Diﬀerence. Spear-
man correlation was used to analyze the degree of correlation
between SDMA and the variables age, body weight, blood pressure
(systolic, diastolic, and mean arterial pressure), hematocrit, serum
creatinine concentration, blood urea nitrogen concentration, and
thyroxine concentration. P-values were adjusted by false discovery
rate q-values and were considered signiﬁcant when <0.05. To explore
which factors most signiﬁcantly inﬂuenced SDMA, a random forest
algorithm was trained by 10-fold cross-validation with 80% of the
data, and subsequently tested on the remaining 20% of the data.23
Variables included in training the regression model included those
for which correlation analysis was performed as well as group (car-
diac, diabetic, renal, control), breed, sex, neutering, and, for the car-
diac group, the presence or absence of congestive heart failure or
systolic anterior motion of the anterior mitral leaﬂet (SAM). Splitter
importance was computed on the basis of minimizing the root-
mean-squared error (RMSE), and the 10 most important features
from the random forest model were extracted.
Results
The study population was drawn from a total of 121
cats. Twenty-seven cats were excluded based on the
above criteria, leaving a ﬁnal study population of 94
cats distributed as 17 cats in the renal group (16 cats
with CKD, 1 cat with CKD and obstructive
ureterolithiasis), 40 cats in the cardiac group (all with
HCM, 16 of which had SAM and 5 of which were in
congestive heart failure based on clinical and echocar-
diographic ﬁndings), 17 cats in the diabetic group, and
20 healthy control cats. Demographic data for each
group are presented in Table 1. Blood pressure mea-
surements were available for 15 cats in the renal group,
all cats in the cardiac group, 10 cats in the diabetic
group, and 10 healthy controls.
Median (range) serum SDMA for the renal group
(positive control) was 19 (10–93) lg/dL, whereas for the
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control group (negative control), it was 10 (5–15) lg/
dL. For the cardiac and diabetic groups, serum SDMA
was 9 (4–24) lg/dL and 7 (3–11) lg/dL, respectively.
The renal group had signiﬁcantly higher serum SDMA
and creatinine concentrations compared to all other
groups, whereas the diabetic group had signiﬁcantly lower
serum SDMA and creatinine concentrations compared to
all other groups. No signiﬁcant diﬀerence was found
between the cardiac group and the control group for either
variable (Figs 1 and 2). No signiﬁcant inﬂuence on SDMA
concentration was found for either age (P = 0.17) or inter-
action between age and group (P = 0.42). However, a sig-
niﬁcant inﬂuence on serum creatinine concentration was
found for the interaction between age and group
(P = 0.006), but not for age alone (P = 0.46).
Correlation analyses identiﬁed a signiﬁcant correla-
tion only between serum SDMA and creatinine concen-
trations (R2 = 0.53; P < 0.001).
The ﬁnal random forest model applied to the data
was selected after 10-fold cross-validation by generation
of 500 trees. Model results were R2 = 0.39 and
RMSE = 1.96 when evaluated on the randomly selected
20% of the data not used for model training (the test
data). Predictors with the 10 highest variable impor-
tance scores are shown in Figure 3.
Discussion
Our study investigated the possible inﬂuence of HCM
and DM on serum SDMA in cats.
Unlike what has been reported in humans,11 cats
with HCM in our study did not have serum SDMA
concentrations signiﬁcantly diﬀerent from those of
healthy controls. The cause of increased serum SDMA
concentrations in humans with HCM has not been
determined, but it has been speculated to be related to
shear stress which increases the activity of arginine
methyltransferase,24 the enzyme responsible for produc-
tion of SDMA and its counterpart, asymmetric
dimethylarginine. The obstructive form of HCM, which
is associated with higher shear stress, is associated with
the highest SDMA concentrations in humans.11 Shear
stress in cats with HCM is most evident with the fre-
quent occurrence of SAM,25 which was present in 16 of
40 cats in our study. Interestingly, SAM was not
among the variables identiﬁed by the random forest
model as important predictors of serum SDMA in our
study.
Although most of the included cats had occult heart
disease, 5 cats had clinical and echocardiographic evi-
dence of congestive heart failure at the time of presen-
tation. Previous studies in humans and pigs have
suggested an association between serum SDMA and
severity of cardiac disease26,27 In our study, however,
there was no indication of increasing serum SDMA
concentrations in cats with heart failure. In fact, this
small group of cats had serum SDMA concentrations
in the lower half of the cardiac group range, and HCM
as a whole did not appear to inﬂuence serum SDMA.
Nevertheless, a study including a larger number of cats
Table 1. Demographic data of included cats.
Group n Breeds Sex Age (years) Body Weight (kg)
Renal 17 11 DSH, 2 NFC, 2 DLH, 1 RB, 1 MB 7 FN, 10 MN 11 (4–17) 4.8 (2.4–7.0) (n = 15)
Cardiac 40 17 MC, 15 BSH, 4 NFC, 2 ESH, 2 DSH 4 FE, 9 FN, 4 ME, 23 MN 6.5 (1–15) 6.0 (3.4–8.6) (n = 39)
Diabetic 17 12 DSH, 2 NFC, 3 Ocicats 5 FN, 1 ME, 11 MN 9 (6–16) 5.8 (3.2–8.9) (n = 17)
Control 20 11 DSH, 4 BSH, 2 NFC, 2 Somalis, 1 Burmese 3 FE, 11 FN, 6 MN 7 (3–15) 5.0 (3.4–6.8) (n = 19)
BSH, British shorthair; DSH, Domestic shorthair; DLH, Domestic longhair; ESH, Exotic shorthair; MB, Mixed breed; MC, Maine
coon; NFC, Norwegian forest cat; RB, Russian blue; FE, Female entire; FN, Female neutered; ME, Male entire; MN, Male neutered.
Fig. 1. Serum SDMA concentrations of the control group, diabetic group, cardiac group, and renal group. Median and interquartile
ranges are shown as horizontal lines. Statistical signiﬁcance between groups is symbolized as P < 0.05 = *, P < 0.01 = **, or
P < 0.001 = ***.
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with more severe stages of heart disease and no concur-
rent renal disease would be required to conﬁrm this
ﬁnding.
Keeping in mind the eﬀect of SDMA on endothelial
function described in humans, it is perhaps not surpris-
ing that the biomarker has been associated with the
severity of coronary atherosclerosis.26,28 In humans with
HCM, evidence of endothelial dysfunction has been
detected along with and possibly caused by a
simultaneous increase in serum SDMA.11 Although
abnormal coronary vasculature also is believed to be an
important part of the pathophysiology in HCM in
cats,11,17 atherosclerosis is uncommon in this species.29
Considering our results, the link between serum SDMA
and endothelial dysfunction might not be as evident in
cats.
Another important ﬁnding of our study was the sig-
niﬁcantly lower serum SDMA concentrations in cats
Fig. 2. Serum creatinine concentrations of the control group, diabetic group, cardiac group, and renal group. Median and interquartile
ranges are shown as horizontal lines. Statistical signiﬁcance between groups is symbolized as P < 0.05 = *, P < 0.01 = **, or
P < 0.001 = ***.
Fig. 3. Predictors of SDMA in a population of 94 cats (control group, diabetic group, cardiac group, and renal group) were determined
through a random forest algorithm including the variables age, body weight, blood pressure (systolic, diastolic, and mean arterial pressure),
hematocrit, creatinine, blood urea nitrogen, thyroxine, group, breed, sex, neutering, and, for the cardiac group, the presence or absence of
systolic anterior motion of the anterior mitral leaﬂet (SAM) and congestive heart failure. Predictors with the top 10 highest variable impor-
tance scores are presented. BUN, Blood urea nitrogen; BW, Body weight; NFO, Norwegian forest cat; FN, Female neutered; ME, Male
entire; MN, Male neutered.
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with DM compared to controls. It was mirrored by
concurrently lower serum creatinine concentrations in
the same group of cats. Previous studies have not found
cats with DM to have lower serum creatinine concen-
trations compared to healthy cats, but these studies
included DM cats with concomitant CKD which may
have obscured the results.21,30 Serum creatinine concen-
tration is known to decrease with muscle wasting in
older animals, which may oﬀset the increase expected to
occur as GFR decreases. However, SDMA is not
aﬀected by muscle wasting, and an eﬀect of age on
SDMA previously detected in older cats was found to
be related to older cats having lower GFR.31 Accord-
ingly, the decreased serum SDMA concentrations of the
diabetic group are not believed to be related to muscle
wasting, but considered related to the disease itself, a
ﬁnding that was supported by the random forest analy-
sis in which belonging to the diabetic group was among
the most important predictors of SDMA. Nevertheless,
weight also was a predictor in the analysis, but cats
with DM had comparable weight to those of the con-
trol group (Fig 3, Table 1). Optimally, a speciﬁc mea-
sure of muscle mass rather than weight would have
been beneﬁcial for evaluation of these cats, and, in the
absence of such information, the cause of the lower
serum creatinine concentration in this group cannot be
conclusively determined.
In humans, unlike in cats, diabetic nephropathy is
the leading cause of renal disease.18 Diabetic patients
furthermore have increased risk of clinical cardiovascu-
lar disease.32 Higher concentrations of serum SDMA,
therefore, would be expected to be more frequent in
humans with DM. However, results are conﬂicting.
One study19 found SDMA to be a reliable marker of
GFR in children with type 1 DM, whereas another
study20 found lower serum SDMA concentrations in
people with poorly controlled type 2 DM than in
healthy controls. In accordance with the latter study, it
has been shown that humans with evidence of insulin
resistance have lower serum SDMA concentrations.13,33
Possible mechanisms include increased cellular uptake
or enhanced elimination in response to hyperﬁltration.33
Additionally, it has been suggested that hepatic metabo-
lism of SDMA could be upregulated in patients with
insulin resistance.33,34 Insulin resistance is known to be
an important factor in development of DM in cats,35 an
interesting fact, because results of our study mirror stud-
ies of humans with type 2 DM. Pathophysiologically, it
is likely that hyperﬁltration and osmotic diuresis are the
most important factors leading to decreased serum
SDMA concentrations in DM, especially in patients with
poorly controlled DM. Of the 17 cats with DM included
in our study, 6 were newly diagnosed, and 4 were still
undergoing adjustment of their insulin treatment, which
would make hyperﬁltration particularly likely in the
diabetic group. Furthermore, 1 cat was excluded from
the study because of concomitant CKD and DM. Inter-
estingly, this cat had a normal serum SDMA concentra-
tion despite CKD, which possibly could be related to
concurrent DM. Accordingly, although these ﬁndings
should be conﬁrmed by future prospective studies,
SDMA might be less valuable as a test of early CKD in
cats with DM.
Interestingly, although the renal group was included
as the positive control of our study, 5 cats with renal
disease did, in fact, have serum SDMA concentrations
within the reference range. The cause of this ﬁnding
is unknown, but serves as a reminder that SDMA
does not have perfect sensitivity, and always should
be interpreted in light of other clinical information.
Similarly, 1 healthy control cat did have a mildly
increased serum SDMA concentration. We chose to
not exclude this cat from the study to avoid biasing
the data by deﬁning groups by the variable on which
they were compared. Repeated data analysis with-
out this cat, however, did not alter the conclusions.
Early renal disease in this cat is a possibility, and
optimally should have been investigated by GFR
measurement.
The main limitation of our study is its retrospective
design. However, both cases and controls were
included from previous prospective studies carried out
by the authors, who had been personally responsible
for the systematic data collection from each animal.
The individual disease groups were rather small, espe-
cially when evaluating the subset of cats with conges-
tive heart failure, and larger studies are required to
conﬁrm our ﬁndings. A speciﬁc limitation was lack of
radiographic conﬁrmation of congestive heart failure
for this small group. However, all cats had severely
enlarged left atria and corresponding clinical signs,
and, for 4 of the 5 cats, conﬁrmation of failure was
achieved by echocardiographic detection of pleural
ﬂuid, pericardial ﬂuid, or both. Serum sample storage
time is also a possible limitation. Samples had been
stored at 80°C for a maximum of 6 years, but,
although long-term stability studies on SDMA still are
needed, a recent study in dogs showed that SDMA
was unaﬀected by multiple freeze-thaw cycles and
stable after 2 weeks at room temperature.36 Hence,
SDMA is considered a biomarker of high stability.
Finally, an important limitation is the lack of available
urinalysis data for the cardiac group. Although
included cats were nonazotemic, some may have had
IRIS stage 1 disease. One cat, moreover, was receiving
furosemide treatment at presentation which also could
have inﬂuenced its serum SMDA concentration. How-
ever, because the cardiac group had serum SDMA con-
centrations indistinguishable from those of the control
group, these possible confounders are considered of
limited importance.
In conclusion, we did not ﬁnd an inﬂuence of
HCM on serum SDMA concentration in cats. There-
fore, SDMA may be a reliable marker of GFR in
cats with HCM. Studies evaluating a larger number
of cats with severe stages of HCM are required, how-
ever, to conﬁrm these ﬁndings. Cats with DM had
signiﬁcantly lower serum SDMA concentrations than
did healthy controls, a ﬁnding that needs further
investigation. The possible eﬀect of hyperﬁltration
should be kept in mind when evaluating renal func-
tion in cats with DM.
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Footnotes
a IDEXX Laboratories. Vet Med Labor GmbH, M€orikestrasse 28/
3, D-71636 Ludwigsburg, Germany
b “R” version 3.4.0. for Microsoft Windows. R Development Core
Team (2008). R: A language and environment for statistical com-
puting. R Foundation for Statistical Computing, Vienna, Aus-
tria. ISBN 3-900051-07-0, URL http://www.R-project.org
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